Coeptis Therapeutics, Inc.COEPNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
102.29%
↑ 128% above average
Average (29q)
44.94%
Historical baseline
Range
High:987.15%
Low:-100.00%
Volatility
2419.2%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 102.29% |
| Q2 2025 | 235.00% |
| Q1 2025 | -74.80% |
| Q4 2024 | -57.64% |
| Q3 2024 | 103.55% |
| Q2 2024 | -48.68% |
| Q1 2024 | -23.32% |
| Q4 2023 | -80.02% |
| Q3 2023 | 987.15% |
| Q2 2023 | 304.61% |
| Q1 2023 | 0.00% |
| Q4 2022 | -100.00% |
| Q3 2022 | 0.00% |
| Q2 2022 | 0.00% |
| Q1 2022 | 0.00% |
| Q4 2021 | 0.00% |
| Q3 2021 | 0.00% |
| Q2 2021 | 0.00% |
| Q1 2021 | 0.00% |
| Q4 2020 | 0.00% |
| Q3 2020 | 0.00% |
| Q2 2020 | 0.00% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |
| Q4 2005 | 0.00% |
| Q3 2005 | 0.00% |
| Q2 2005 | 0.00% |
| Q1 2005 | 0.00% |
| Q4 2004 | 0.00% |
| Q3 2004 | 0.00% |